Plasminogen Activator Inhibitor-1 Is Involved in Streptozotocin-Induced Bone Loss in Female Mice

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 3.
FIG. 3.

Effects of PAI-1 deficiency on diabetes-induced impairment of osteogenic differentiation in both sexes of mice. mRNA levels of Runx2 (A), osterix (B), and ALP (C) as well as protein levels of Runx2, ALP, and β-actin (D) in tibia of control and streptozotocin-treated male PAI-1 WT and KO mice. mRNA levels of Runx2 (F), osterix (G), and ALP (H) as well as protein levels of Runx2, ALP, and β-actin (I) in tibia of control and streptozotocin-treated female PAI-1 WT and KO mice. Data are expressed relative to β-actin mRNA values and expressed as means ± SEM. *P < 0.05, **P < 0.01 (n = 5–7 in each group). The levels of serum osteocalcin in control and streptozotocin-treated male (E) and female (J) PAI-1 WT and KO mice. Results are expressed as means ± SEM. *P < 0.05, **P < 0.01 (n = 5–7 in each group). Cont, control; STZ, streptozotocin.

This Article

  1. Diabetes vol. 62 no. 9 3170-3179